SKIN CARE


A natural solution for atopic skin


Mélanie Coirier, Mélanie Mangier, Emilie Lasjaunias, Elodie Aymard, Brigitte Closs - Silab


Atopic dermatitis (AD) is a pathology including symptoms such as pruritus, redness, dry skin and eczema lesions, and characterised by alternating periods of flares and remissions. During a flare, the skin of patients is dry with red patches, patches and aesthetic unpleasantness, accompanied by intense itching. Depending on patient age, body areas


affected vary from cheeks, arms and abdomen in children, to skin folds in older subjects. This pathology has considerable negative repercussions on the quality of life of patients and also on that of their entourage. Itching causes insomnia and treatments are costly and chronic.1 Currently affecting 15-20% of children


and 1-3% of adults, its incidence throughout the world is rising and increasing attention is being paid to identifying the risk factors which contribute to the appearance of AD, notably climate, pollution, beauty routine and psychology. In the context of a pandemic, the prolonged use of personal protective equipment (friction caused by wearing a mask, for example) and hand washing with detergents and sanitisers may catalyse this phenomenon. From a molecular standpoint, alterations


leading to the appearance of this pathology are increasingly better characterised. The major anomalies of AD are: ■ Alteration of the barrier function, possibly resulting from a mutation of the filaggrin gene, a key gene of epidermal differentiation. This causes excessive water loss, leading to skin dryness. In addition, the penetration of allergens and microorganisms is favoured by the skin’s increased permeability ■ Exacerbated inflammatory response: Two responses are concomitantly implemented following the penetration of foreign elements. A non-specific inflammatory response is begun by keratinocytes. It is characterised by the secretion of cytokines such as interleukin (IL)-8 and above all thymic stromal lymphopoietin (central cytokine in atopic dermatitis). The second response involves immune cells, in particular Th2 lymphocytes. This latter is characterised by the production of a number of interleukins such as IL-4, IL-13 and IL-31 ■ Modification of the cutaneous microbiota: The efficacy of innate immune defences is reduced because of the inflammatory state of the skin. Cytokines produced by Th2 lymphocytes have a considerable effect on the production of antimicrobial peptides


www.personalcaremagazine.com ABSTRACT Figure 1: Ophiopogon japonicus (mondo grass)


(HBD2, HBD3 and RNase 7) by keratinocytes. These mediators combat the installation of the pathogenic bacterial species Staphylococcus aureus. Colonisation by S. aureus is favoured because of the insufficient production of these peptides in the course of atopic dermatitis ■ Neuronal hyperreactivity: The inflammatory state of atopic skin is also the cause of a major symptom of pruritus. The cytokines that are released (TSLP, IL-31, etc.) act directly on cutaneous neurons by activating specific receptors on their surface (TSLPR, IL-31R). This bonding causes the activation of the pruritus receptor TRPA1 and the initiation of a pruritogenic response Faced with these elements, Silab developed


AD-Resyl® (hereafterOphiopogon japonicus root extract). This is a purified natural active ingredient, composed of oligosaccharides that are obtained from the roots ofOphiopogon japonicus (mondo grass) (Figure 1) via an eco-extraction process. It is able to restore the homeostasis of atopic skin. Indeed, a 3D in vitro model2


demonstrated


the mechanism of action of the Ophiopogon japonicus product in targeting the previous mentioned four main anomalies. At the level of individuals, Ophiopogon japonicus root extract’s therapeutic efficacy leads to a considerable improvement of patient’s quality of life, as shown by the clinical studies in Caucasian adults and children3 and also in Asian adults.


Atopic dermatitis is an inflammatory and chronic disease that today affects 15-20% of children and 1-3% of adults. Epidemiological studies show that this pathology is an emerging public health problem. AD is a multifactor skin disorder with genetic and environmental components. Moreover, a health crisis linked to all hygiene procedures and protection measures may amplify its emergence and consequences. Pruritus, redness, dry skin and eczema lesions are among the most common symptoms. To tackle this pathology, Silab developed a purified natural active ingredient obtained from the roots of Ophiopogon japonicus (mondo grass). It is able to prevent the appearance of clinical signs of atopic dermatitis and to prolong periods of remission, as a relay to corticosteroid treatments. Its clinical efficacy in a cohort of Asian adult patients with this pathology has been demonstrated under control by dermatologists.


Materials & methods The clinical study was conducted between September 2015 and April 2016 in order to determine the effect of the Ophiopogon japonicus root extract formulated at 0.5% in a cream on maintaining the remission phase of atopic dermatitis in Asian adults, as a relay for corticosteroid treatment. The effect was assessed after 30 and 60 days of twice-daily application and compared with a placebo formula. This study, which was conducted in


collaboration with the dermatology laboratory of the General Air Force Hospital in Beijing, included 76 Asian male and female subjects, between 16 and 62 years of age (mean age 39), under the control of dermatologists. To be included in the study, subjects had to


with atopic skin,


be older than 16 with slight to moderate atopic dermatitis, localised on the members and/or body, with flare-ups happening at least once every two months. They also had to have prior prescription of a dermocorticoid. Criteria for exclusion were: ■ Being treated systemically with corticosteroids, antibiotics, immunosuppressors or having used topical dermocorticoids, antibiotics, antihistamines or calcineurin- inhibiting type immunosuppressors within the preceding three weeks


March 2022 PERSONAL CARE


67


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84